Philippe Laffont’s Ginkgo Bioworks DNA Stock Holding History

Philippe Laffont’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-198,443	Closed	-$18.9M	–	86
2022 Q2	$18.9M	Buy	+198,443	New	+$24.2M	0.23%	57

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Philippe Laffont's DNA Position: Q3 2022 in Review

Philippe Laffont sold out of Ginkgo Bioworks (DNA) in Q3 2022, closing a stake of 198,443 shares — an estimated $18.9M sold.

Philippe Laffont first reported a position in DNA in Q2 2022 and held it in 1 quarter. The position peaked at $18.9M in Q2 2022. 278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

Philippe Laffont reported no remaining Ginkgo Bioworks position as of Q3 2022 after selling out during the quarter.
Philippe Laffont sold 198,443 Ginkgo Bioworks shares in Q3 2022, an estimated $18.9M.
Philippe Laffont first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 1 quarter.
Philippe Laffont's Ginkgo Bioworks position peaked at $18.9M in Q2 2022.
278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Coatue Management's 13F filing for Q3 2022, filed 14 Nov 2022.